Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Conditions

• Hematologic Neoplasms

Interventions

• DRUG: Panobinostat

Sponsor

Novartis Pharmaceuticals